Welcome to our dedicated page for Iveda Solutions SEC filings (Ticker: IVDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Iveda Solutions, Inc. (NASDAQ: IVDA) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Here, investors can review Forms 10‑K and 10‑Q for detailed information on Iveda’s business, financial condition, and risk factors, along with current reports on Form 8‑K that disclose material events related to its AI video analytics, smart city, and IoT operations.
Iveda’s filings confirm that its common stock and common stock purchase warrants trade on The Nasdaq Stock Market LLC under the symbols IVDA and IVDAW. A notable Form 8‑K describes how the company received a Nasdaq notice regarding non‑compliance with certain continued listing standards tied to stockholders’ equity, market value of listed securities, or net income, and later reported stockholders’ equity above the minimum threshold, leading Nasdaq staff to determine that Iveda complied with the rules and to close the matter.
The company’s DEF 14A definitive proxy statement offers insight into corporate governance, including the annual meeting of stockholders, the election of directors, and the ratification of the independent registered public accounting firm. It also outlines record dates, voting procedures, and the rights of stockholders whose shares are held directly or in street name.
On Stock Titan, these filings are paired with AI-powered summaries that help explain complex disclosures in clear language. Users can quickly understand key points from lengthy 10‑K and 10‑Q reports, track significant 8‑K events such as listing compliance updates, and review proxy materials without reading every page. The platform also surfaces relevant information about capital structure, such as the registration of IVDA and IVDAW, and helps investors monitor how regulatory filings reflect Iveda’s evolving smart city, AI video analytics, and IoT strategies.
Iveda Solutions, Inc. is conducting a primary offering of 5,259,999 shares of common stock and pre-funded warrants to purchase up to 454,287 shares, together with 5,714,286 Series X Warrants to buy up to 11,428,572 shares, plus 400,000 placement agent warrants. The common stock and Series X Warrants are priced at $0.35 per share-and-warrant unit, with pre-funded units priced at $0.3499, for total gross proceeds of $1,999,971 and estimated net proceeds of $1,859,971 before expenses. Each Series X Warrant is exercisable immediately at $0.35 per share for two years, and each pre-funded warrant is exercisable at $0.0001 per share until fully exercised. Common shares outstanding are expected to increase from 5,879,741 to 11,139,740 after the stock issuance, excluding warrant exercises. The company plans to use proceeds for general corporate purposes, including software R&D, working capital, debt repayment, capital spending, acquisitions and other corporate initiatives, while warning of significant risks including going concern doubts, continued losses, customer concentration, Taiwan exposure and potential Nasdaq delisting if listing standards are not maintained.
Iveda Solutions, Inc. has filed an amended S-1 to offer up to 5,434,782 shares of common stock, together with up to 5,434,782 pre-funded warrants and up to 5,434,782 Series X warrants to buy up to 10,869,564 additional shares, on a reasonable best efforts basis. The assumed combined price is $0.92 per share and accompanying Series X warrants, matching the last Nasdaq Capital Market close on January 28, 2026.
The company, recently redomiciled to Delaware, develops AI-driven video analytics and IoT-based smart city platforms, with most revenue generated by its Taiwan subsidiary. It has a going concern opinion, accumulated losses of about $51 million through December 31, 2024, and relies heavily on a small number of key customers. There is no minimum offering amount or escrow, so investor funds become immediately available even if limited capital is raised, and the new securities will dilute existing holders, with common shares outstanding rising from 5,879,741 to 11,314,523 if all shares (but no warrants) are sold.
Iveda Solutions, Inc. is conducting a reasonable best efforts primary offering of up to 5,434,782 shares of common stock at an assumed combined price of $0.92 per share together with Series X warrants to purchase up to 10,869,564 additional shares. The company may instead issue up to 5,434,782 pre-funded warrants in lieu of common stock for investors constrained by 4.99% or 9.99% ownership limits, with each pre-funded warrant exercisable at $0.0001 per share.
The Series X warrants are exercisable upon issuance at $0.92 per share and expire two years after issuance. Common stock outstanding was 5,879,741 shares before the offering and is expected to be 11,314,523 shares after the offering, excluding existing options and warrants. Iveda highlights significant risks, including a going concern opinion, accumulated losses of roughly $51–53 million, heavy reliance on its Taiwan subsidiary for most revenue, customer concentration, and the possibility of Nasdaq delisting if listing standards are not maintained.
Iveda Solutions, Inc. (IVDA) has resolved a prior Nasdaq listing deficiency. On May 27, 2025, the company was notified that it did not meet Nasdaq Capital Market standards requiring at least $2,500,000 in stockholders’ equity, or a $35 million market value of listed securities, or $500,000 of net income from continuing operations for continued listing. Based on its Form 10-Q for the quarter ended September 30, 2025, Iveda reported $3,768,242 of stockholders’ equity. Nasdaq staff advised on November 25, 2025 that the company now complies with these rules and the listing matter is closed.
Iveda Solutions, Inc. (IVDA) filed a prospectus supplement registering up to 1,296,876 shares of common stock issuable upon exercise of outstanding Series A, Series B and placement agent warrants. Alongside this, the company reported Q3 2025 revenue of $1.65 million, down from $2.40 million a year earlier, but narrowed its net loss to $221,304 from $581,373 as gross margin improved. For the nine months ended September 30, 2025, revenue rose to $4.65 million from $4.28 million and the net loss improved to $1.58 million from $2.47 million, helped by lower operating expenses. Cash, restricted cash and equivalents totaled $3.33 million at period end, and Iveda subsequently raised $2.22 million of additional equity via its at-the-market program. Despite these improvements, management and the auditor concluded that recurring losses and negative operating cash flow raise substantial doubt about the company’s ability to continue as a going concern.
Iveda Solutions, Inc. (IVDA) filed a prospectus supplement that updates an existing resale registration covering warrants to purchase 411,185 shares of common stock and pre-funded warrants to purchase 273,685 shares of common stock, incorporating its latest Quarterly Report on Form 10-Q for the period ended September 30, 2025.
For the nine months ended September 30, 2025, Iveda generated total revenue of $4.65 million, up from $4.28 million a year earlier, with most sales coming from Taiwan government and commercial customers. The company reduced its net loss to $1.58 million from $2.47 million, and total stockholders’ equity increased to $3.77 million, helped by equity issuances including at-the-market sales. Cash, restricted cash and equivalents were $3.33 million at period end, and an additional $2.22 million was raised in October 2025.
Despite these improvements, management and the auditors state that recurring losses, negative operating cash flow and an accumulated deficit of $54.76 million raise substantial doubt about Iveda’s ability to continue as a going concern.
Iveda Solutions, Inc. is updating a prospectus covering warrants to purchase 235,625 shares of common stock at $34.00 per share, by incorporating its latest Form 10-Q. For the quarter ended September 30, 2025, revenue was $1.65 million, down from $2.40 million a year earlier, but the net loss narrowed to $0.22 million from $0.58 million as operating expenses fell. For the nine-month period, revenue rose to $4.65 million from $4.28 million and the net loss improved to $1.58 million from $2.47 million.
Cash, restricted cash and equivalents were $3.33 million, supported by equity raises including 1,599,383 shares sold through an at‑the‑market program for net proceeds of $2.71 million, plus an additional 1,373,809 shares in October 2025 for $2.22 million. Despite these financings and improved results, the company reports an accumulated deficit of $54.76 million and states that there is substantial doubt about its ability to continue as a going concern.
Iveda Solutions (IVDA) filed its Q3 2025 10‑Q, showing lower quarterly revenue but a smaller loss. Q3 revenue was $1,651,787 versus $2,398,162 a year ago, with gross profit of $517,277. Operating loss narrowed to $214,303 and net loss to $221,304 (from $581,373). For the nine months, revenue reached $4,654,270, up from $4,278,983, while net loss improved to $1,579,225.
Cash and cash equivalents were $3,298,474 at September 30, 2025, and stockholders’ equity was $3,768,242. Management disclosed substantial doubt about the company’s ability to continue as a going concern due to ongoing losses and negative operating cash flows. The company raised capital through an at‑the‑market program, selling 1,599,383 shares for net proceeds of $2,706,346 year‑to‑date and, subsequently in October, 1,373,809 shares for $2,224,048.
Customer concentration remains high: four customers accounted for 66% of revenue for the nine months, primarily in Taiwan. Common shares outstanding were 4,457,444 as of September 30, 2025, and 5,874,741 as of October 31, 2025.
Iveda Solutions (IVDA) director reports share disposition. A Form 4 shows a director disposed of 20,331 shares of common stock on 10/21/2025 at a price of $1.28 per share. Following the transaction, the reported beneficial ownership was 0 shares, held directly. The form was signed by Robert D. Gillen.